The present disclosure describes IFN-纬 gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for...
The present disclosure describes IFN-纬 gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for...
The present disclosure describes IFN-纬 gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for...
Here, we present the predictive value of the 10-gene IFN-y expression signature algorithm (based on Ayers etal.) for pathologic response and relapse in a cohort of melanoma pts treated with neoadjuvant IPI + NIVO.Methods:Baseline tumor biopsies from lymph node metastases of stage III melanoma ...
The present disclosure describes IFN-纬 gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for...
The present disclosure describes IFN-纬 gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for...